The key feature of polyglutamine aggregates accumulating in the course of Huntington disease (HD) is their resistance to protein denaturants, and to date only chaperones are proved to prevent mutant protein aggregation. It was suggested that expanded polyglutamine chains (polyQ) of mutant huntingtin are cross-linked to other proteins such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Here we clarify the roles of GAPDH and molecular chaperone Hsp70 in the formation of sodium dodecyl sulfate (SDS)-insoluble polyQ aggregates. First, the addition of pure GAPDH was found to enhance the aggregation of polyQ in a cellfree model of HD. Secondly, the immunodepletion of GAPDH dose-dependently decreased polyQ aggregation. Finally, siRNA-mediated inhibition of GAPDH protein in SK-N-SH neuroblastoma cells has also reduced the aggregation of cellular polyQ. Regulated over-expression of Hsp70 decreased the amount of GAPDH associated with SDS-insoluble polyQ aggregates. Physical association of Hsp70 and GAPDH in SK-N-SH cells was shown by reciprocal immunoprecipitation and confocal microscopy. Pure Hsp70 dose-dependently inhibited the formation of polyQ aggregates in cell-free model of HD by sequestering both GAPDH and polyQ. We demonstrated that Hsp70 binds to polyQ in adenosine triphosphate-dependent manner, which suggests that Hsp70 exerts a chaperoning activity in the course of this interaction. Binding of Hsp70 to GAPDH was nicotinamide adenine dinucleotide-dependent suggesting another type of association. Based on our findings, we conclude that Hsp70 protects cells in HD by removing/sequestering two intrinsic components of protein aggregates: the polyQ itself and GAPDH. We propose that GAPDH might be an important target for pharmacological treatment of HD and other polyglutamine expansion-related diseases.
INTRODUCTION
A large group of neurodegenerative diseases is associated with polyglutamine chain expansion in normal cellular proteins. For instance, mutations in huntingtin (Htt) protein cause Huntington disease (HD), mutations in ataxins lead to spinocerebellar ataxias (SCA, types 1, 2 and 3) and mutations in the androgen receptor are associated with spinobulbular muscular atrophy (SBMA). Polyglutamine expansions (polyQ) are usually excised from the mutated proteins and form sodium dodecyl sulfate (SDS)-insoluble aggregates. The aggregates accumulate in nuclei and, through yet not fully understood mechanisms, kill neural cells (1, 2) .
Currently, two mechanisms are provided to explain the formation of polyQ aggregates. According to the 'polar zippers' model, polyglutamine polypeptides can form beta-sheet structures where every 20 amino acids are folded in an anti-parallel manner and stabilized by hydrogen bonds between their amides. These zipper-like structures may act as a nucleation seed for the formation of aggregates (3, 4) . Another model describes the cross-linking of glutamines in some proteins, such as Htt, to lysines present in other proteins in a process catalysed by tissue transglutaminase (tTG) (5, 6) . The involvement tTG in the pathogenesis of HD is supported by the observation that tTG inhibitor cystamine considerably improved the motor function and enhanced the survival in mouse models of HD (7) . Studies have also demonstrated that caspase-mediated excision of polyglutamine tracts from the pathogenic protein is a prerequisite for the tTG reaction (8) . Subsequent cross-linking of glutamines to lysines by tTG leads to the formation of aggregates that cannot be dissolved by strong denaturants, such as sodium dodecylsulphate or guanidine hydrochloride (6) .
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a ubiquitous cellular enzyme, was found to be a source of amines for tTG (9) . It was demonstrated that tTG can use three GAPDH lysine residues (K191, K270 and K333) as a substrate, covalently linking them to both long (43 amino acids) and short (17 amino acids) polyglutamine peptides (10) . GAPDH is a glycolytic enzyme which catalyses the phosphorylation of glyceraldehyde-3-phosphate using nicotinamide adenine dinucleotide (NAD + ) as a cofactor. GAPDH is also involved in cellular processes that are not directly related to glycolysis, such as translation, activity of ion channels and regulation of transcription (11, 12) . In addition, GAPDH has been implicated in the pathogenesis of polyQ expansion diseases (13, 14) . GAPDH is sequestered in polyQ aggregates in post-mortem sections of HD patients' brains and in transgenic mice expressing Htt gene with 89 CAG repeats (15, 16) . PolyQ-associated aggregation of GAPDH was reproduced in cell models of HD, SCA-1 and SBMA (17, 18) . For example, HD fibroblasts were characterized by reduction in GAPDH enzymatic activity as well as oligomerization and nuclear accumulation of the enzyme (19) (20) (21) . However, the role of GAPDH in polyQ aggregate formation remains elusive.
Molecular chaperones provide cells with natural protection against protein aggregation or improper folding (22) (23) (24) . Hsp70 and DnaJ-like chaperones universally suppress polyQ toxicity and promote cell survival as demonstrated in various models of human neurodegenerative diseases, such as transgenic Drosophila and polyQ-expressing mammalian cells (25 -27) . On the other hand, the reduction in Hsp70 alone can lead to effects reminiscent of polyQ-mediated cellular degeneration. For instance, the loss of Hsp70 has been shown to aggravate neurodegeneration in R6/2 mice (28). Hsp70 promotes increased solubility of polyQ proteins by associating with polyQ aggregates in a dynamic and transient manner (29, 30) . The protective effect of Hsp70 overexpression is more evident at the early stages of aggregate formation, i.e. before the nucleation of fibrils (31) .
Although the beneficial role of Hsp70 in HD is supported by several studies, the molecular mechanism of Hsp70-mediated anti-aggregate function is not understood. We have hypothesized that Hsp70 inhibits polyQ aggregation by preventing its association with GAPDH. In this work, we explored the involvement of GAPDH in the aggregation of polyQ and how this is suppressed by Hsp70. Our findings are relevant to the pathology of HD and other polyQ-related disorders.
RESULTS
GAPDH plays a key role in the formation of insoluble polyglutamine aggregates in cellular and cell-free models of HD The role of GAPDH in polyQ aggregate formation was studied using a cellular model of HD. For this purpose, SK-N-SH neuroblastoma cells were transfected with vectors providing the expression of two forms of Htt fused to the enhanced green fluorescent protein (EGFP): a mutated form of exon 1 of Htt containing 103 glutamines and a short form containing 25 glutamines (Q103-EGFP and Q25-EGFP, respectively). Cells were analysed by the confocal fluorescent microscopy 2 days after the transfection. Q103-EGFP was found in large aggregates (Fig. 1A, lower panel and insert) , while Q25-EGFP showed diffuse cytoplasmic distribution in all tested cells (Fig. 1A, upper panel) . Staining with anti-GAPDH antibody demonstrated co-localization of GAPDH with both Q103-EGFP and Q25-EGFP (Fig. 1A) .
Western blotting of cellular extracts demonstrated that GAPDH was present in SDS-insoluble aggregates in SK-N-SH cells over-expressing Q103. Cells were transfected with either Q25 or Q103, and 2 days after transfection, whole cell extracts were analysed by SDS electrophoresis. In order to detect SDS-insoluble aggregates, proteins from both resolving and stacking gels were transferred to the blotting membrane and stained with anti-GAPDH or anti-EGFP antibodies. Anti-GAPDH antibodies recognized a 37 kDa monomer of GAPDH in both Q25-and Q103-expressing cells (Fig. 1B) . However, an insoluble form of GAPDH appeared only in samples derived from cells over-expressing Q103 (Fig. 1B) . Therefore, the expression of mutant Htt promoted the aggregation and cross-linking of GAPDH. It was also noted that monomer GAPDH was presented on western as a double 35 -37 kDa band. It is possible that the recruitment of GAPDH into SDS-insoluble aggregates triggers an excision of GAPDH, thus producing a lower molecular weight fragment; alternatively, this fragment can be a result of partial degradation of the enzyme or an oxidation of certain sulphhydryl groups.
A filter trap assay was employed to study the protein aggregation under cell-free conditions. Whole cell extracts were prepared from cells expressing Q103 8 h after transfection. In preliminary experiments, it was found that at this time cells already express Q103-EGFP but the aggregation of the protein is not prominent. Q103 continue to aggregate in cellular extracts and the extent of aggregation can be measured by trapping the aggregated protein on acetate cellulose membrane and by staining the membrane with anti-EGFP antibody (Fig. 1C) . To address the role of GAPDH in the formation of polyQ aggregates, indicated amounts of pure GAPDH were added to a subset of samples and the extent of polyQ aggregation was analysed 34 h later. It was found that GAPDH dose-dependently enhanced Q103 aggregation (Fig. 1C) but did not promote the aggregation of Q25 (data not shown).
This finding was confirmed by GAPDH neutralization experiments. Cellular extracts usually contain a considerable amount of endogenous GAPDH; therefore, the amount of the endogenous GAPDH was reduced by immunodepletion
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Human Molecular Genetics, 2011, Vol. 20, No. 20 using anti-GAPDH polyclonal anti-serum and Protein G Sepharose beads. As demonstrated by western blotting, the anti-GAPDH anti-serum dose-dependently removed GAPDH from cellular extracts and the amount of the removed GAPDH negatively correlated with the amount of aggregated Q103 (Fig. 1D, low panel) . Notably, the depletion of GAPDH Forty-eight hours after the transfection, the aggregation of GAPDH in cells was analysed by western blotting. Proteins were transferred to the blotting membrane from both stacking and resolving gels. GAPDH was identified using a specific antibody to GAPDH. (C) GAPDH promotes mutant Htt aggregation in vitro. SK-N-SH cells were transfected with Q103. Cellular extracts were prepared 8 h after the transfection and the indicated amounts of pure GAPDH were added to the extracts. After that, reaction mixtures were incubated for 34 h at 378C. The formation of aggregates was analysed with the aid of filter trap assay using anti-EGFP antibody. (D) GAPDH removal diminishes Q103 aggregation in vitro. SK-N-SH cellular extracts were prepared 6 h after transfection with Q25 or Q103 vector. The extracts were depleted of GAPDH by incubation with indicated amounts of anti-GAPDH antibodies (indicated in digits) or with 40 ml of non-immune serum as a control (indicated as NS) in the presence of Protein G Sepharose beads. After 1.5 h of incubation, beads were removed from extracts and the amount of GAPDH bound to the beads was analysed by western blotting using anti-GAPDH antibody (upper panel); the lysates were allowed to incubate for the next 34 h. The amount of polyQ remained after GAPDH immunodepletion was measured with the aid western blotting using anti-EGFP antibody (middle panel). The aggregation of Htt was analysed by a filter trap assay using an anti-EGFP antibody (lower panel). (E) Inhibition of GAPDH expression impairs aggregation of mutant Htt in SK-N-SH cells. Cells were transfected with plasmid expressing GAPDH siRNA or non-specific (Mock) siRNA (Ambion). Forty-eight hours later, the GAPDH expression level was analysed by western blotting using an anti-GAPDH antibody (upper panel). The amount of polyQ in cells after GAPDH knockdown was measured with the help of western blotting (middle panel). To assess Htt aggregation, cells expressing GAPDH siRNA for 40 h were transfected again with either Q25 or Q103. Twenty hours after the second transfection, the aggregation of Htt was analysed by a filter trap assay using an anti-EGFP antibody (lower panel). (F) GAPDH-binding drugs inhibit mutant Htt aggregation. SK-N-SH cells were incubated with indicated amounts of drugs after transfection with the Q103 plasmid. Forty-eight hours after the transfection, cells containing aggregates were counted and then analysed with a filter trap assay. The intensity of dots after filter trap assay was estimated with the use of TotalLabQuant software.
did not affect the amount of Q103 (Fig. 1D , middle panel).
Our data indicate that beforehand depletion of GAPDH dosedependently reduces the aggregation of polyQ.
In the next experiment, GAPDH expression was reduced using GAPDH-specific siRNA (Fig. 1E) . Although GAPDH is an abundant cellular protein, siRNA effectively reduced its level in SK-N-SH cells and this reduction correlated with the amount of aggregated Q103, as demonstrated in the filter trap assay (Fig. 1D, upper panel) . Similar to immunodepletion experiments, the reduction in the GAPDH level in cells had no influence on Q103 amount, suggesting that the recruitment of GAPDH is an early event in polyQ aggregation process ( Fig. 1D and E, middle panel).
GAPDH was reported to interact with a number of chemicals having neuroprotective properties. In the next series of experiments, some of these drugs were tested for their ability to inhibit polyQ aggregation. Particularly, monoamine oxidase B inhibitor R-(2)-Deprenyl (hereafter, deprenyl) is used in clinic primarily for treatment of early-stage Parkinson's disease. Deprenyl was shown to prevent neuronal cell death by inhibiting nuclear translocation of GAPDH and its interaction with Siah1 (32) . Earlier works have demonstrated that GAPDH physically binds deprenyl and its derivatives (33) . To test whether deprenyl can affect polyQ aggregation, Q103-expressing cells were treated with various concentrations of the drug for 48 h. The number of cells with aggregates was compared with the total number of cells expressing Q103-EGFP. It was found that at 10 nM, deprenyl reduced the number of cells with polyQ aggregates by 20% (Fig. 1F) . However, further increase in the deprenyl concentration up to 1 mm only marginally reduced polyQ aggregation in these cells. The extent of polyQ aggregation was also monitored in the filter trap assay that confirmed deprenyl to be a potent inhibitor of polyQ aggregation (Fig. 1F , lower panel).
In the next experiment, we employed an inhibitor of serine proteases 4-(2-aminoethyl)benzenesulphonylfluoride (Pefabloc, AEBSF), which was previously reported to form a stable complex with GAPDH (34) . Earlier studies demonstrated that Pefabloc can inhibit beta-amyloid formation; however, it was never investigated in relation to HD. In our experiments, Pefabloc was found to reduce the polyQ aggregation in the cell-free conditions as well as the number of cells with aggregates. Specifically, 1 mM Pefabloc reduced the number of cells with polyQ aggregates by 60% (Fig. 1F) . Thus, both the cellular and cell-free models of HD suggest that GAPDH plays an active role in polyQ aggregation.
Over-expression of Hsp70 reduces aggregation of both polyQ and GAPDH
A number of studies have demonstrated that Hsp70 plays protective role in neurodegenerative pathologies, including HD. However, the mechanism of Hsp70-mediated protection remains elusive. To analyse Hsp70 involvement in polyQ aggregation, SK-N-SH human neuroblastoma cells conditionally over-expressing Hsp70 were generated by transfection of the cells with human hsp70 gene under control of the metallothionein promoter (35) . Increasing Zn 2+ concentration in culture media led to a dose-dependent increase in the Hsp70 level in SK-N-SH-hsp70 cells, as demonstrated by western blotting with anti-Hsp70 antibody ( Fig. 2A) . Cell examination by microscopy revealed that the induction of Hsp70 in SK-N-SH-hsp70 cells after their transfection with the Q103 plasmid reduced the number of cells with aggregated polyQ in a dose-dependent manner (Fig. 2B) . At 150 mM Zn 2+ , the number of cells with aggregates was reduced by 60%.
The Hsp70-mediated inhibition of aggregation was accompanied by the reduction in SDS-insoluble polyQ and GAPDH. Western blotting showed that the Zn 2+ -mediated increase in the Hsp70 level caused dose-dependent accumulation of monomer Q103 in resolving gel and the concomitant disappearance of the SDS-insoluble Q103-positive band in the stacking gel (Fig. 2C) . When the same samples were stained with anti-GAPDH antibodies, Zn 2+ -mediated increase in the Hsp70 level was found to correlate with the reduction in the amount of SDS-insoluble GAPDH in the stacking gel (Fig. 2D) .
Finally, cell-free experiments confirmed that Hsp70 reduced the aggregation of both polyQ and GAPDH. Increased amounts of pure human recombinant Hsp70 were added to extracts prepared from cells transfected with the Q103-EGFP vector. The cellular extracts were then incubated for 34 h and subjected to ultrafiltration, and the membrane was probed with antibodies specific to either EGFP or GAPDH as described earlier in the text. It was found that the addition of pure Hsp70 dose-dependently reduced the amount of both aggregated polyQ and GAPDH (Fig. 2E ).
Hsp70 interacts with GAPDH
To test whether Hsp70 interacts with GAPDH in neuroblastoma cells, SK-N-SH cells were co-transfected with plasmids expressing Hsp70 fused to red fluorescent protein (DsRedHsp70) and GAPDH fused to EGFP (EGFP-GAPDH). Confocal fluorescent microscopy revealed that both fusion proteins were localized primarily in the cytoplasm, although a weak positive signal was also noted in the nucleus (Fig. 3A) . To detect the physical association between Hsp70 and GAPDH, co-immunoprecipitation studies were performed. Extracts were prepared from SK-N-SH-hsp70 cells induced with 100 mM ZnSO 4 to accumulate Hsp70. In the first experiment, anti-Hsp70 polyclonal antibodies were used to precipitate Hsp70 protein complexes followed by western blotting using anti-GAPDH antibody. In the second experiment, anti-GAPDH polyclonal antibodies were used to precipitate GAPDH protein complexes followed by western blotting with an anti-Hsp70 antibody (Fig. 3B) . It was found that the Hsp70 -GAPDH complex can be detected irrespective of which antibody is used for immunoprecipitation and that both proteins are present in the complex stoichiometrically. Furthermore, when the amount of expressed Hsp70 was varied by using different concentrations of Zn 2+ , the higher amount of immunoprecipitated Hsp70 pulled down the higher amount of GAPDH (Fig. 3C ).
Hsp70 prevents aggregation in the HD model by binding to both GAPDH and polyQ
Knowing that Hsp70 binds to GAPDH, we hypothesized that this association may prevent GAPDH involvement in the process of polyQ aggregation. To test this possibility, we incubated extracts prepared from Q103-expressing SK-N-SH cells with indicated amounts of pure Hsp70. After one and half hours of incubation with the chaperone, anti-Hsp70 polyclonal antibody was added for 2 h followed by addition of Protein G Sepharose beads. The beads were removed by centrifugation and bound protein complexes were subjected to electrophoresis and immunoblotting. The remaining extracts were further incubated for 34 h before the analysis by the filter trap assay. The removal of Hsp70 led to dose-dependent removal of GAPDH and its depletion from aggregates as evidenced by staining of dots with the anti-GAPDH antibody (Fig. 4A, upper and lower panel) . Hsp70-mediated inhibition of polyQ aggregation was analysed similarly except that membranes from both western blotting and filter trap assay were stained with anti-EGFP antibody. Hsp70 was found to remove polyQ from cellular extracts in a dose-dependent manner and the amount of polyQ trapped on filters after the depletion was much lower (Fig. 4B, upper panel and lower  panel) . Immunoprecipitates were analysed by western blotting using both anti-GAPDH and anti-Hsp70 antibodies. (C) Over-expressed Hsp70 binds to endogenous GAPDH. SK-N-SH-hsp70 cells were incubated with the indicated amounts of ZnSO 4 . Eighteen hours later, cellular extracts were prepared and used for immunoprecipitation with anti-Hsp70 antibody and Protein G Sepharose. Equal amount of total protein was used for each reaction. Immunoprecipitates were analysed by western blotting using an anti-GAPDH antibody (clone 6C5).
Q103 plasmid. Cellular lysates were prepared 6 h after transfection. One hundred micrograms of cellular extract were incubated for 34 h with the indicated amount of pure Hsp70. Q103 aggregation was analysed by a filter trap assay using anti-EGFP and anti-GAPDH antibodies. The intensity of dots after filter trap assay was estimated with the use of TotalLabQuant software.
The data presented in this part of the study indicate that Hsp70 binds to two critical components of growing mutant Htt aggregates, i.e. polyQ and GAPDH, and that this binding strongly reduces the amount of SDS-insoluble material.
Hsp70 chaperone uses different mechanisms to remove GAPDH and polyQ from aggregates
Since Hsp70 associates with two different components of polyQ aggregates, we analysed the mechanistic basis for these interactions using a protein -protein interaction assay. In this assay, adenosine triphosphate (ATP) was used to differentiate a chaperone activity of Hsp70 and NAD + to affect GAPDH, as it is known to maintain GAPDH in a tetrameric form. Human recombinant Hsp70 was immobilized on 96-well microtitre plate and, after a blocking for non-specific binding, extracts of Q25-or Q103-expressing SK-N-SH cells were added to wells followed by antibodies against either GAPDH or EGFP and secondary anti-mouse antibody conjugated with peroxidase ( Fig. 5A and B, upper panel) . In parallel, interactions between the proteins were studied using the filter trap assay after cellular extracts were depleted of Hsp70 with the aid of an anti-Hsp70 antibody (Fig. 5A, B , lower panel, and Fig. 5C ). The scheme for the entire experiment is described in Figure 5D .
First, we found that the interaction between Hsp70 and GAPDH was only weakly affected by ATP, whereas it was strongly inhibited by NAD + , a factor supporting GAPDH in a tetrameric form (Fig. 5A) . Secondly, polyQ binding to Hsp70 can be prevented by both NAD + and, more efficiently, by ATP, indicating the involvement of chaperone activity of Hsp70 (Fig. 5B) . Importantly, when both ATP and NAD + were present in the reaction mixture, interactions between Hsp70 and GAPDH were notably inhibited suggesting two independent mechanisms of their interaction (Fig. 5A and B) . Hsp70 immunodepletion combined with filter trap assay showed an inhibitory effect of NAD + and, to a lesser extent, of ATP on polyQ aggregation as judged by the amount of SDS-insoluble aggregates (Fig. 5A-C) . The presence of both NAD + and ATP reduced Hsp70-mediated anti-aggregation effect in the filter trap assay (Fig. 5C ). We conclude that Hsp70 recognizes GAPDH in a specific manner, which is different from chaperone-like recognition of aggregation-competent polyQ molecules.
DISCUSSION
The cause of death in polyQ-accumulating cells in HD and similar disorders is one of the most intriguing issues in modern neurobiology. There are convincing evidences that cell death in HD involves an inhibition of degradation mechanisms, a disruption of various transcription activators and the release of reactive oxygen species, all of which may finally lead to cell death (2). Many of these mechanisms are closely related to the aggregation of abnormally long polyQ tracts. Therefore, the latter process has become the most promising target for the drug therapy. A variety of proteins is involved in the process of insoluble protein aggregation in cell. Two of them, GAPDH and Hsp70, seems to play opposite roles in polyQ pathology, and our current work provides a foundation for mechanistic understanding of this process.
The results showing possible participation of GAPDH in the aggregation of mutant proteins, including amyloid precursor (36) and amyloid-beta (37, 38) in the course of Alzheimer's disease and mutant alpha-synuclein, a pathogen in Parkinson's disease (39) , indicate that GAPDH is involved in these pathogenic mechanisms as well. A similar option for GAPDH to participate in the aggregation of polyQ was suggested by Ruoppolo et al. (10) who demonstrated that specific lysines on the GAPDH molecule are cross-linked with glutamyl residues. Thus, we made two suggestions: (i) GAPDH can be implicated in the formation of large SDS-insoluble aggregates in a complex with mutant Htt and (ii) the process of aggregate formation may be prevented by the Hsp70 chaperone which is able to trap the components of the GAPDH -polyQ complex. In order to prove the implication of GAPDH in polyQ aggregation, we employed several approaches. The analysis of the cell extract containing growing aggregates with the aid of the gel-retardation assay showed that both GAPDH and polyQ are found in the stacking gel, and both, therefore are components of growing SDS-insoluble aggregates. These data affirm the involvement of GAPDH in polyQ aggregation corroborating earlier observations in brain slices from HD patients (15) and in HD-imitating cells (17) . Another important observation was that by regulating the amount of the enzyme, one is able to change the size of the aggregates dose-dependently (Fig. 1C and D) . Finally, down-regulation of GAPDH expression with siRNA also led to the reduction in polyQ aggregation (Fig. 1E) .
Hsp70 chaperone has been shown to be a most promising molecule for the therapy of polyQ-related diseases. It has been suggested that Hsp70 itself or Hsp70 assisted by a DnaJlike protein traps the oligomers of polyQ and inhibits their 'sticking' to each other (29, 40, 41) . In this study, we found that, in addition to trapping polyQ molecules, Hsp70 is able to suppress polyQ aggregation by reducing the amount of available GAPDH. Using SK-N-SH cells inducibly overexpressing Hsp70 and cell-free HD model, we found that Hsp70 was able to deplete GAPDH from the incipient aggregates ( Fig. 2C-E) .
The only way to obtain such dissociating activity of the chaperone is to tightly bind the enzyme. The existence of such complex was proved by immunofluorescence and co-immunoprecipitation studies (Fig. 3) . Our results correspond well to the data of Grossmann et al. (42) which demonstrated that immobilized Hsp70 specifically recognized several peptide fragments of GAPDH. Two of three lysine residues, K270 and K333, exposed on the surface of the enzyme molecule and recruited to form covalent bonds with polyQ chains (9) were found to match with the Hsp70-binding peptide fragments of GAPDH. These observations led us to suggest that there can be a specific interaction of a portion of GAPDH molecules with Hsp70.
Such interactions cause trapping a significant part of GAPDH from the cross-linking action of tTG; this was convincingly demonstrated in experiments performed with the use of cell-free HD model: the removal of the chaperone together with the enzyme caused the reduction in SDS-insoluble material (Figs 2 and 4) . That effect was complemented by the inhibition of polyQ aggregation due to direct interaction between Hsp70 and polyQ (Fig. 4) .
To test what kind of interaction exists between the three proteins, we designed a novel protein -protein interaction assay employing the extracts of HD-imitating cells. We added either ATP or NAD + , or both to the incubation mixture trying to influence protein -protein-specific interactions. The data show that polyQ interacted with Hsp70 in an ATP-dependent manner, while the binding of GAPDH was strongly reduced by NAD + and was dependent on ATP to a much lesser extent (Fig. 5) . Furthermore, co-immunoprecipitation of polyQ and GAPDH with the chaperone from the extracts containing ATP had no meaningful effect on aggregation, while the dissociation of the Hsp70 complex with GAPDH by NAD + strongly reduced the amount of SDS-insoluble material retained on the filter (Fig. 5C) . However, the addition of both dissociating factors to the extract did not affect aggregation at all or the factors somehow neutralize the effect of each other. We can only speculate on the character of the Hsp70 -GAPDH interaction, and in the context of this report, it seems most important that the chaperone selectively takes a considerable proportion of GAPDH molecules away of the control of tTG. This selection appears to be rather specific and in our mind, Hsp70 targets dimeric or monomeric GAPDH rather than the tetrameric form since the interaction can be suppressed by NAD + . Figure 5 . Data of protein-protein interaction assay prove different requirements for the binding of Hsp70 to GAPDH and polyQ. (A and B) Pure recombinant human Hsp70 was immobilized on the surface of a 96-well EIA plate and after blocking non-specific binding, the extract of SK-N-SH cells overexpressing polyQ with or without (Mock) additives as indicated were applied to wells followed by GAPDH-(A) or EGFP-specific (B) antibodies (upper panel). The above cellular extracts were subjected to immunoprecipitation with the anti-Hsp70 polyclonal antibody according to standard protocol (see Materials and Methods for details) and precipitated proteins were further analysed with the aid of western blotting and antibodies against GAPDH (A, lower panel) or EGFP (B, lower panel). (C) The extracts of polyQ over-expressing SK-N-SH cells supplied with the above additives were depleted of Hsp70 with the aid of immunoprecipitation as described in (A) and (B) and the remaining protein mixtures were incubated and ultrafiltration was applied to collect the aggregated material; the filter trap assay is described in Materials and Methods. The intensity of dots after filter trap assay was estimated with the use of TotalLabQuant software. (D) Schematic representation of the protein-protein interaction assay and its results.
In conclusion, the fact that a proportion of GAPDH molecules is recruited to growing polyglutamine aggregates makes the enzyme an attractive target for pharmacological intervention in the manner of Deprenyl or Pefabloc as demonstrated in Figure 1F . Another target is apparently the Hsp70 chaperone whose induction was convincingly shown to prevent the process of aggregation. Several such substances are already in the course of trials and it seems that the neuroprotective action of celastrol (43) or resveratrol (44) will soon be realized in certain drugs. Finally, in a very recent review, it was claimed that exercise can be a means of releasing Hsp70 in the entire organism and such a factor is noticeable when applied to the therapy of neurodegenerative pathologies, and let us assume other diseases (45) .
MATERIAL AND METHODS

Cell culture
Human neuroblastoma cell line SK-N-SH (ECACC, Porton Down, UK) was propagated in Dulbecco modified Eagle's medium supplemented with 2 mM glutamine, 10% fetal calf serum (Pan-Eco, Moscow, Russia) and 50 mg/ml gentamicin sulphate in 5% CO 2 at 378C.
Plasmids
Mammalian expression vectors containing EGFP fused to the non-pathogenic and pathogenic forms of exon 1 of huntingtin (HttEx1) were a generous gift from Dr David Rubinsztein (Cambridge Institute for Medical Research, Cambridge, UK). A non-pathogenic form of HttEx1 was expressed by plasmid Q25-EGFP, which contains 25 glutamine residues fused to the N-terminus of EGFP. The pathogenic form of HttEx1 was expressed by plasmid Q103-EGFP, which contains 103 glutamine residues fused to the N-terminus of EGFP. The latter was shown to form insoluble aggregates in cells (46) .
Metallothionein-driven pZ-hsp70 + pZem plasmids were used to express human Hsp70 in a regulated manner. In the pZ-hsp70 plasmid, Hsp70 expression is controlled by the metallothionein promoter and, therefore, can be regulated by changing the concentration of Zn 2+ ions. Both plasmids were kindly provided by Dr M. Jäättelä (Danish Cancer Society, Copenhagen, Denmark). GAPDH -EGFP and DsRed -Hsp70 plasmids were generated using the appropriate parental vectors pECFP-C1 and pDsRed1-N1, both from Clontech (Mountain View, USA). Plasmid pMSHsp70, a bacterial expression vector used for the production of recombinant Hsp70, was a generous gift from Dr R. Morimoto, Evanston, USA.
Antibodies
Mouse monoclonal anti-Hsp70, clone 3B5 antibody (47) was used both for immunoprecipitation experiments and western blotting. Anti-GAPDH polyclonal antibody was generated in Balb/c mice using a standard protocol and employing the protein isolated as described below; these antibodies were used for immunoprecipitation. Mouse monoclonal anti-GAPDH monoclonal antibody clone 6C5 was purchased from Millipore-Chemicon (Billerica, MA, USA) and used for microscopy, western blotting and biochemical assays. Anti-EGFP rabbit polyclonal antibody (Abcam, Cambridge, UK) was used for western blotting, immunoprecipitation and the filter trap assay. Goat anti-mouse and anti-rabbit antibodies conjugated with horseradish peroxidase were from Sigma-Aldrich (St-Louis, MO, USA).
Proteins
Recombinant human Hsp70 was purified from bacteria transformed with a pMSHsp70 plasmid. Hsp70 was purified using a two-step chromatography procedure as previously described (48) . Briefly, after lysis, bacterial extracts were passed through a DEAE-Sepharose column equilibrated with buffer A [20 mM NaCl, 20 mM Tris-HCl, 0.2 mM ethylenediaminetetraacetic acid (EDTA), 0.2 mM 1,4 dithio-DL-threitol (DTT), pH 7.5]. Bound proteins, containing Hsp70, were eluted with buffer A containing 0.35 M NaCl. The eluent was incubated with ATP-agarose (Sigma-Aldrich). Hsp70 was eluted by ATP-Mg. Samples were adjusted to 5 mM EDTA and Hsp70 was precipitated with ammonium sulphate [65% (w/v) saturation]. The protein was dissolved in and dialysed against phosphate-buffered saline (PBS) using Pierce Slide-a-Lyser Cassettes (Pierce, Rockford, IL, USA). Hsp70 solution was further cleaned by incubation with polymyxin B-agarose gel (Sigma) and sterilized by filtration through a 0.2 mm filter (Millipore). Protein concentration was measured according to the Bradford assay (49) .
GAPDH was isolated from rabbit muscles as previously described (50) with an additional purification step, using gel filtration on Sephadex G-100 (Superfine).
Cell transfection
SK-N-SH cells were transfected with Q25-EGFP and Q103-EGFP plasmids with the aid of Lipofectamine 2000 reagent according to the manufacturer's instructions (Invitrogen Life Technologies, Carlsbad, CA, USA). SK-N-SH cells were transfected with metallothionein-driven pZ-hsp70 + pZem plasmids (kindly provided by Marja Jäättelä, Copenhagen, Denmark). After transfection, stable transfectants were selected on genecitine (1000 mg/ml, Gibco/ BRL, USA). Hsp70 expression was induced by 25-150 mM ZnSO 4 for 18 h.
Anti-GAPDH siRNA (4390849) and negative control siRNA (4390843) were purchased from Ambion, USA. Transfections were performed using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's guidelines.
Confocal microscopy
SK-N-SH cells were grown on coverslips in 24-well plates (Sarstedt, Leicester, UK) until the density reached 2.5 . 10 4 cells per well. Cells were transfected with plasmids as indicated in the text. Typically, 48 h after transfection, cells were fixed with 4% paraformaldehyde for 20 min followed by cold 96% ethanol for 5 min. The efficiency of transfection was monitored by counting both green fluorescent and non-fluorescent cells for studies involving Q25-EGFP, Q103-EGFP and GAPDH -EGFP. For both Q25-EGFP and Q103-EGFP studies, the transfection efficiency was routinely found to be 35-50%. To localize endogenous GAPDH, cells were stained with anti-GAPDH antibody (6C5) and secondary Cy3-labeled antibody (Jackson ImmunoResearch Europe Ltd, Suffolk, UK). SK-N-SH cells cotransfected with GAPDH -EGFP and DsRed -Hsp70 were processed and analysed similarly.
Slides were examined with the aid of a LSM510 Zeiss or Leica TCS SL confocal microscope using 488 nm as the excitation wavelength for EGFP, and 543 nm for both Cy3 and DsRed. Images were analysed with the LSM5 Image Browser program. The size of inclusions was measured using Zeiss LSM Image Examiner version 2.80.1123. Counting of aggregates in transfected SK-N-SH cells was done with the aid of an Axiovert 40 C/40 CFL (Carl Zeiss, Thornwood, NY, USA).
Western blotting and immunoprecipitation
To induce exogenous Hsp70 expression, SK-N-SH-hsp70 cells were incubated with 25, 50, 75, 100 and 150 mM ZnSO 4 for 18 h. Cells were lysed in sodium dodecyl sulfate -polyacrylamide gel electrophoresis (SDS -PAGE) buffer with 5% 2-mercaptoethanol. Samples were normalized by cell number. Specifically, a sample corresponding to 5 × 10 For co-immunoprecipitation studies, cells were washed with PBS (pH 7.4), lysed on ice in RIPA buffer (250 ml) and then spun at 13 000g for 10 min. To the supernatant, 5 ml of anti-Hsp70 (3B5) or mouse polyclonal anti-GAPDH antibody were added, and the mixture was gently rotated at 48C for 4 h. Protein G-agarose (10 ml) was then added, and the incubation was continued for an additional 90 min. Protein G-agarose was collected by centrifugation and the beads were washed three times with 50 mM Tris -HCl, pH 8.0, containing 150 mM NaCl and 1% (v/v) Nonidet P-40. The protein G-agarose slurry was suspended in double Laemmli SDS sample buffer and heated at 908C for 5 min. Immunoprecipitated proteins were analysed on a 10% polyacrylamide gel followed by transfer onto a polyvinylidene difluoride membrane (0.4 mm) in 25 mM Tris, 192 mM glycine and 20% (v/v) methanol. Membranes were incubated with an antibody against GAPDH or Hsp70 or EGFP in different experiments.
The formation of large polyglutamine-EGFP aggregates was analysed using the method of Zhou et al. (51) with modifications. Concentrations of both acrylamide and of methylene-bisacrylamide in the stacking gel were reduced to 3.5 and 0.085%, respectively. SK-N-SH-hsp70 cells were preincubated with indicated ZnSO 4 concentrations for 18 h before a second transfection with either Q25-EGFP or Q103-EGFP. Forty-eight hours later, cells were lysed using SDS -PAGE buffer without 2-mercaptoethanol. Samples corresponding to 5 × 10 4 cells were loaded per lane. Membranes were probed with either anti-EGFP or anti-GAPDH antibody (ab9484, Abcam).
PolyQ aggregation assay
SK-N-SH cells were transfected with Q25-EGFP or Q103-EGFP plasmids. When newly synthesized green fluorescent proteins became visible ( 8 h after transfection), cells were collected. Cells were washed twice with cold PBS and then lysed by three freeze-thaw cycles in buffer containing 25 mN Tris -HCl, 20 mM NaCl, 1 mM EDTA, pH 8.0. Protein concentrations were adjusted to 1 mg/ml. These lysates were used in the following protein binding tests. Lysates, 200 mg in each probe, were incubated for 36 h on a rotating shaker with purified GAPDH or purified Hsp70 in the amounts indicated in the appropriate section. To remove endogenous GAPDH, mouse polyclonal anti-GAPDH serum (10, 20, 40 or 80 ml) was added to lysates for 1.5 h and after pulling out the antibodies with the aid of ProteinG Sepharose (Sigma), the lysates were allowed to incubate for the next 34 h. In another set of experiments, different amounts of Hsp70 were added to the lysates for 2 h. Proteins were immunoprecipitated with anti-Hsp70 antibody followed by ProteinG-Sepharose; then, samples were incubated for another 34 h. After all these incubations, the aggregation of proteins was analysed by the filter trap assay.
Filter trap assay
Cell lysates were sonicated, incubated at 988C for 2 min and 50 ml of the extract was filtered through a 0.22 mm cellulose acetate membrane. The membrane was pre-equilibrated with three washes of SDS wash buffer (10 mM Tris-HCl, pH 8.0; 150 mM NaCl; 0.1% SDS). A dot blotter apparatus was used for the application of samples. Twenty minutes after the application of samples, the membrane was washed twice in SDS wash buffer, blocked in PBS containing 5% fat-free milk and 0.1% Tween 20 and probed with the antibody against either EGFP or GAPDH as indicated in the text. Quantification of dot intensity was performed with the aid of TotalLabQuant software.
In vitro interaction assays
All procedures were performed at 378C unless indicated otherwise. Human recombinant Hsp70 was diluted to a concentration of 4 mg/ml in PBS and immobilized for 1 h on a F96 MicroWell TM plate (Nunc, Roskilde, Denmark). The plate was washed with PBS and blocked for 1 h with PBS containing 3% fetal bovine serum (FBS/PBS). Immobilized Hsp70 was then incubated for 1.5 h with cellular extracts prepared as follows. SK-N-SH neuroblastoma cells transfected with 103Q were extracted 8 h after the transfection in buffer, containing 25 mN Tris -HCl, 20 mN NaCl, 1 mN EDTA, pH 8.0. The extract was diluted in tris-buffered saline (TBS) containing 10 mM MgCl 2 (TBS-Mg) so that the final concentration of total protein was 60 mg/ml. The extract was then divided to receive either a dissociating factor or a vehicle. Dissociating factors were added at this stage at concentrations indicated
